Navigation Links
Westaim announces 2008 year-end results
Date:2/18/2009

CALGARY, Feb. 18 /PRNewswire-FirstCall/ - The Westaim Corporation announced today that for the year ended December 31, 2008, it recorded a net loss of $10.2 million, or 11 cents per share, on revenues of $22.4 million compared to a net loss of $58.0 million, or 62 cents per share, on revenues of $31.8 million in the previous year. For the three months ended December 31, 2008, the Company posted a net income of $2.7 million, or 3 cents per share, compared to a net loss of $26.8 million, or 28 cents per share, in the same period in the previous year.

The loss from continuing operations for the year ended December 31, 2008 was $1.7 million compared to a loss of $2.8 million in 2007. At the operations level, this improvement resulted from lower manufacturing and research and development costs compared to 2007 and $4.9 million of severance costs included in the 2007 results, all of which was offset by $10.1 million milestone revenue earned by NUCRYST Pharmaceuticals Corp. in 2007. The improvement in results also benefitted from a $7.3 million favourable change in foreign exchange gains as a result of the stronger U.S. dollar in 2008 as well as lower write-downs in the value of asset-backed commercial paper (ABCP). These improvements were partially offset by an $8.7 million gain on the sale of real estate in 2007. The loss from discontinued operations, which includes windup and operating costs at the Company's wholly owned subsidiary, iFire Technology Ltd., declined significantly in 2008 to $8.5 million compared to $55.2 million in 2007. This improvement is the result of reduced operating costs of $26.7 million and lower severances and net asset write-downs in 2008 compared to 2007.

At December 31, 2008, Westaim had $46.8 million in consolidated cash and cash equivalents, compared to $31.0 million at December 31, 2007. Westaim's cash position, excluding cash and cash equivalents held by its 74.7 per cent owned subsidiary NUCRYST Pharmaceuticals Corp
'/>"/>

SOURCE Westaim Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. The Westaim Corporation update on status of short-term investments
2. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Third Quarter Results
3. Westaim announces 2007 third quarter results
4. Westaim reduces ABCP exposure
5. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2007 Fourth Quarter Results
6. Westaim announces 2007 year-end results
7. Webcast Advisory - The Westaim Corporation Webcast of Annual Meeting of Shareholders
8. Westaim announces 2008 first quarter results
9. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Second Quarter Results
10. Westaim announces 2008 second quarter results
11. Westaim announces sale of iFire Technology Ltd. assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... This Fourth of July, Peacock ... Alley story including hard work, tenacity, perseverance, commitment to quality, honesty and love of ... Born of Mary Ella Gabler's simple love of quilts, Peacock Alley was fully realized ...
(Date:6/29/2015)... ... 2015 , ... Sublime Beauty NATURALS® introduces its new USDA Certified Organic Sesame ... natural skincare and even culinary uses, was especially designed for Oil Pulling. , ... Oil Pulling can accomplish this. Oil Pulling is an Ayurvedic practice that is easy ...
(Date:6/29/2015)... ... June 30, 2015 , ... With thousands of children in ... in a much-needed autism support center, planned at Utah Valley University, in Orem, Utah. ... for the center and the building in which it will be housed. , Utah ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one ... Dr. John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons ...
(Date:6/29/2015)... ... 29, 2015 , ... The Society for Immunotherapy of Cancer ... granted accelerated approval of Bristol-Myers Squibb’s Opdivo® (nivolumab) for the treatment of metastatic ... of nivolumab for patients with metastatic melanoma in Europe represents a major advance ...
Breaking Medicine News(10 mins):Health News:Luxury Linen Purveyor Peacock Alley Celebrates the Fourth of July 2Health News:New Product: Transform Wellness and Oral Health With This Ancient Ayurvedic Secret and Organic Product from Sublime Beauty NATURALS® 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 2Health News:doTERRA Partners With Utah Valley University on Autism Support Center 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 2Health News:Society for Immunotherapy of Cancer Reacts to EMA Approval of Nivolumab for Treatment of Metastatic Melanoma 3
... a voluntary,recall of two types of its Meijer Brand dry-roasted ... in all of its stores in Michigan, Ohio,Indiana, Illinois and ... stations. All sell-by dates are impacted by this recall. , ... items:, -- Meijer Bulk Dry Roasted Peanuts, ...
... 2 alcohol-metabolizing enzymes are responsible, study says , , ... the DNA of certain genes can increase the ... according to researchers who reviewed studies on alcohol ... analysis suggests that such variations, called gene polymorphisms, ...
... Clinicians in an increasing number of countries can now ... the clinical management of osteoporosis. , FRAX, which ... February 2008. It was developed by Professor John A. ... Metabolic Bone Diseases at the University of Sheffield Medical ...
... Partners, a national,investment banking firm headquartered in Nashville, ... as a senior research analyst covering the,healthcare services ... to Avondale Partners from Credit Suisse in New ... behavioral health care providers.,Prior to that he covered ...
... Physicians Healthcare Management Group, Inc. (Phyhealth) ... maintenance organizations (HMOs) in partnership with physicians and ... malpractice insurer, today released the following letter to ... year, a new Congress and a new administration ...
... these treatments for menopausal symptoms, FDA says , , ... as "bio-identical" hormones or "bio-identical hormone replacement therapy," ... menopausal women lose weight to preventing senility. , ... effective than conventional hormone-replacement therapy. , But the ...
Cached Medicine News:Health News:Meijer Announces Voluntary Recall for Some Meijer Brand Peanuts and Ice Cream Novelties Citing Possible Health Risk 2Health News:Variations in Gene DNA Boost Drinkers' Cancer Risk 2Health News:FRAX tool now available for use in 12 countries 2Health News:Avondale Partners Expands Coverage With Healthcare Analyst 2Health News:Phyhealth Provides Update to Shareholders 2Health News:Phyhealth Provides Update to Shareholders 3Health News:Phyhealth Provides Update to Shareholders 4Health News:The Truth About 'Bio-identical' Hormone Therapy 2Health News:The Truth About 'Bio-identical' Hormone Therapy 3Health News:The Truth About 'Bio-identical' Hormone Therapy 4
(Date:6/29/2015)... 29, 2015 The Parenteral Drug Association is ... Board of Professional Engineers and Land Surveyors ... to professional engineers for continuing professional competency (CPC) credits. ... value and quality of PDA,s professional education offerings," said ... and hands-on professional training at the Training and Research ...
(Date:6/29/2015)... , June 29, 2015  VisionCare Ophthalmic ... visual prosthetic devices for the treatment of ... publication of "Long-Term (60-month) Results for the ... Stratified by Age in Patients with End-Stage ... . The 5-year data show substantial retention ...
(Date:6/29/2015)... June 29, 2015 Dermatological drugs ... revenues ,Where is the market for dermatological drugs heading? ... Visiongain ,s new report shows you potential revenues and ... Our 310 page report provides ... areas in the industry and the future market prospects. ...
Breaking Medicine Technology:Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 2Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 3Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 4Five-Year Data Demonstrates Long Term Effectiveness and Safety of VisionCare's Telescope Implant for Macular Degeneration in Patients 65 Years and Older 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8
... at the 2011 Pharmaceutical Care Management Association (PCMA),s ... President and CEO Eric Elliott speak about the ... managers as health care reform is implemented, industry ... the market and the pipeline of new treatments ...
... DALLAS, Feb. 8, 2011 ... known for its expertise in understanding consumer data, translating ... effective creative with measurable results, today announced that Peter ... Strategy - Healthcare.  Dannenfelser, a pharmaceutical marketing executive with ...
Cached Medicine Technology:Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 2Peter Dannenfelser Joins Targetbase as Vice President of Strategy, Bringing 15 Years of Pharmaceutical Marketing Experience 3
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
Medicine Products: